bluebird bio (BLUE) said Friday that it agreed to be acquired by funds managed by The Carlyle Group (CG) and SK Capital Partners.
Under the terms of the deal, bluebird shareholders will receive $3.00 per share in cash and a contingent value right of $6.84 per share, payable in cash if bluebird's current product portfolio earns $600 million in net sales in any trailing 12-month period before or ending Dec. 31, 2027. The contingency potentially raises the acquisition price to $9.84 per share.
The company expects David Meek, former chief executive of Mirati Therapeutics and Ipsen, to be named CEO of bluebird when the deal closes. It also said Carlyle and SK Capital will provide the company with primary capital for commercial delivery of gene therapies for patients with sickle cell disease, thalassemia, and cerebral adrenoleukodystrophy.
Trading in shares of bluebird bio on the Nasdaq stock market has been suspended and is expected to resume at 8:00 ET.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。